Prevention of esophageal cancer may be possible through dietary modification or supplementation. In this study we have investigated the mutation preventive properties of ellagic acid, green tea, and diallyl sulfide (DAS) against the mutagenicity of the nitrosamine N-nitrosomethylbenzylamine (NMBA) in the esophagus of the rat. In addition, the effect of the consumption of ethanol on the mutagenicity of NMBA was examined. NMBA is specific in inducing tumors in the rat esophagus and has been used in many studies investigating the mechanism and the prevention of this cancer. We found that the type of mutations induced by two 2-mg/kg subcutaneous injections of NMBA in the lacI gene of "Big Blue" rats is consistent with that found previously for nitrosamines in other systems and consists of G:C-->A:T transitions. We report that the addition of ellagic acid to the feed, replacing drinking water with green tea, and gavage with DAS significantly reduced the mutagenicity of NMBA. In contrast, the addition of 5% ethanol to the drinking water increased the mutagenicity of NMBA. This is consistent with findings that these compounds modulate NMBA-induced carcinogenesis in the rat.

Download full-text PDF

Source
http://dx.doi.org/10.1207/s15327914nc5002_6DOI Listing

Publication Analysis

Top Keywords

mutagenicity nmba
12
rat esophagus
8
ellagic acid
8
green tea
8
drinking water
8
nmba
6
chemoprotection n-nitrosomethylbenzylamine-induced
4
n-nitrosomethylbenzylamine-induced mutation
4
rat
4
mutation rat
4

Similar Publications

Article Synopsis
  • The study investigates the presence of nitrosamine-related impurities and AZBT in sartan medications, classifying them as human mutagens and carcinogens based on long-term treatment effects.
  • A new, efficient method was developed for simultaneous quantification of these impurities using reversed-phase liquid chromatography combined with tandem mass spectrometry.
  • The method showed high extraction efficiency, wide linear range, and strong recovery rates, and was applied to analyze 16 losartan samples, finding AZBT in some but no nitrosamine impurities in any.
View Article and Find Full Text PDF
Article Synopsis
  • The mechanisms behind the development of skin tumors are still not fully understood, particularly regarding the roles of photosensitivity and phototoxicity.
  • Recent studies have linked specific nitrosamines, contaminants in common pharmaceuticals, to gene and phototoxicity in humans, raising concerns about their potential carcinogenic effects.
  • Long-term use of contaminated medications may contribute to skin cancer risk by interfering with tumor suppressor genes and activating oncogenes, affecting overall cancer development.
View Article and Find Full Text PDF

Evaluation of a Novel LC-MS/MS Based Analytical Method for the Risk Assessment of Nitrosamines in Pharmaceutical Products and Packaging Materials.

J Pharm Sci

June 2024

World Medicine İlaç San. Tic. A.Ş, 15 Temmuz Mah. Camiyolu Cd. No:50, K.4, 34212, Bağcılar, İstanbul, Türkiye. Electronic address:

The detection of nitrosamine impurities, particularly small dialkyl types, which are frequently known to be potent mutagenic carcinogens, in some Sartan group active pharmaceutical ingredients (APIs) and finished drug products caused global regulatory organizations to have concerns. Accordingly, Registration Holders/Applicants, API manufacturers, and their raw material suppliers are required to check the presence of nitrosamines in their products and carry out risk assessments using the quality risk management principles specified in the ICH Q9 guide. In this context, a new LC-MS/MS method has been developed and validated for the simultaneous determination of NDMA, NDEA, NMBA, NDIPA, NEIPA, NDBA, and MeNP nitrosamine compounds in API and finished products as well as in primary packaging materials, one of the risk sources.

View Article and Find Full Text PDF

Genotoxicity assessment of eight nitrosamines using 2D and 3D HepaRG cell models.

Arch Toxicol

October 2023

Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA.

N-nitrosamine impurities have been increasingly detected in human drugs. This is a safety concern as many nitrosamines are mutagenic in bacteria and carcinogenic in rodent models. Typically, the mutagenic and carcinogenic activity of nitrosamines requires metabolic activation by cytochromes P450 enzymes (CYPs), which in many in vitro models are supplied exogenously using rodent liver homogenates.

View Article and Find Full Text PDF

Over the last two years, global regulatory authorities have raised safety concerns on nitrosamine contamination in several drug classes, including angiotensin II receptor antagonists, histamine-2 receptor antagonists, antimicrobial agents, and antidiabetic drugs. To avoid carcinogenic and mutagenic effects in patients relying on these medications, authorities have established specific guidelines in risk assessment scenarios and proposed control limits for nitrosamine impurities in pharmaceuticals. In this review, nitrosation pathways and possible root causes of nitrosamine formation in pharmaceuticals are discussed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!